Title

Melatonin as an adjuvant therapy in gestational hypertension and pre-eclampsia: A randomized controlled trial

Authors

Akanksha Lamba Thora^1,*, Pankhudi Singh Jyoti¹ & Anupama Dave²

Affiliation

¹Department of Obstetrics and Gynaecology, MTH Hospital, Indore Madhya Pradesh, India; ²Department of Obstetrics and Gynaecology, MTH Women's Hospital, MGM Medical College, Indore, Madhya Pradesh, India; *Corresponding author

Email

Akanksha Lamba Thora - E-mail: dr.akanksha2709@gmail.com

Pankhudi Singh Jyoti - E-mail: pankhudisingh10@gmail.com
Anupama Dave - E-mail: anupamadave10@gmail.com

Article Type

Research Article

Date

Received November 15, 2025; Revised December 15, 2025; Accepted December 15, 2025, Published December 15, 2025

Abstract

In spite of the improvement of obstetric care, hypertensive disorders of pregnancy have continued to emerge as the major causes of maternal and perinatal morbidity. Therefore, it is of interest to assess the effectiveness of melatonin as an adjuvant treatment in the management of gestational hypertension and pre-eclampsia in 404 pregnant women (183 taking melatonin and 221 taking standard care) in one of the tertiary care hospitals in India. Melatonin group also showed much lower incidences of serious pre-eclampsia that necessitated cesarean section (2.73% vs 8.60, p=0.014), lower rate of proteinuria (28.42 vs 37.10), and a better fetal outcome with a lower incidence of intrauterine death (4.92 vs 9.50). Melatonin supplementation is a potential adjuvant treatment that is promising to decrease the maternal and infant complications in pregnancy-related hypertension disorders.

Keywords

Melatonin, pregnancy, hypertension, pre-eclampsia, adjuvant therapy

Citation

Thora et al. Bioinformation 21(12): 4479-4483 (2025)

Edited by

Vini Mehta

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.